Skip to main
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is poised for significant growth in the sleep-disordered breathing solutions market due to its innovative Genio system and recent strong financial performance, including a 499% year-over-year revenue increase in Q1. With a promising FY26 revenue guidance above analyst expectations and a successful U.S. commercial launch, the company is well-positioned to capture market share through 2026. Additionally, upcoming catalysts such as the ACCCESS study results in June/July 2026 and positive updates on personnel are potential drivers for investor confidence. However, risks include standard adoption challenges, potential cash-burn and regulatory risks associated with the ACCCESS study.

Bears say

Nyxoah is a relatively new company in the medical technology industry, and while they have shown signs of growth in their sales force and revenue projections, their success is contingent on the completion of their ACCCESS study in late June 2026/early July 2026 to potentially obtain label expansion by early-2027. Without this milestone, their outlook may not be as optimistic as projected.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of May 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.